Idorsia (IDRS.F) Earnings Call Presentation

TRYVIO Overview - TRYVIO (aprocitentan) is the only approved therapy for difficult-to-control hypertension [3, 8, 22, 39, 71, 84] - It is the first hypertension therapy targeting the endothelin pathway [1] - TRYVIO represents the first drug from the established ERA class optimized for patients with difficult-to-control hypertension [28] Market Need and Patient Population - Approximately 26 million US patients are not adequately controlled on other drugs and are amenable to TRYVIO [21] - Morbidity and mortality risks are increased in patients with difficult-to-control hypertension, including a 30% increased risk of all-cause mortality, a 44% increased risk of coronary heart disease, a 57% increased risk of stroke, an 88% increased risk of heart failure, and a 95% increased risk of end-stage renal disease [17] Clinical Efficacy and Safety - Aprocitentan demonstrated a rapid double-digit reduction in blood pressure as early as 2 weeks, with a 15.4 mmHg reduction at 4 weeks on top of three antihypertensives [50, 51] - The blood pressure reduction was sustained up to 48 weeks, with a 19.2 mmHg reduction [55, 56] - A major night-time blood pressure decrease was observed with aprocitentan, with an 8.1 mmHg reduction in ambulatory systolic blood pressure [58, 59] - In a phase 2 trial, aprocitentan demonstrated dose-dependent reductions in systolic and diastolic blood pressure, with a maximum reduction of 18.5 mmHg in systolic blood pressure at the 50mg dose [43] - The most common adverse reaction was edema/fluid retention, reported in 9.1% of TRYVIO-treated patients compared to 2.1% in placebo-treated patients [64] High-Risk Populations - In patients with CKD 3/4, aprocitentan showed a 13.4 mmHg reduction in sitting systolic blood pressure and a 10.7 mmHg reduction in daytime ambulatory systolic blood pressure [76] - Aprocitentan 25 mg showed a 56% reduction in microalbuminuria (UACR 30-300 mg/g) and a 67% reduction in macroalbuminuria (UACR >300 mg/g) at week 36 [79]